Literature DB >> 14580035

Botulinum toxin therapy for cervical dystonia.

Francis O Walker1.   

Abstract

Botulinum toxin revolutionized the treatment of cervical dystonia. In contrast to systemically active medications, the effect of botulinum toxin results from selective administration to weaken muscles involved in the dystonic posturing of the head. This article reviews the pathophysiologic basis of symptoms in cervical dystonia and how botulinum toxin alleviates them. Other therapeutic options are reviewed for comparison. This article discusses strategies for maximizing the clinical benefit of botulinum toxin in this disorder and reviews muscle selection and identification with electromyography.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580035     DOI: 10.1016/s1047-9651(03)00045-7

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  8 in total

1.  Comparison between (18)F-FDG PET/CT and EMG Mapping for Identifying Dystonic Superficial Muscles in Primary Cervical Dystonia: Preliminary Results.

Authors:  Su Jin Jang; Joon Young Choi; Duk Hyun Sung; Kwang Hong Park; Ji Young Lee; Sook Kyung Cho; Jang Yu; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

2.  A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis.

Authors:  Harald Hefter; Andreas Kupsch; Martina Müngersdorf; Sebastian Paus; Andrea Stenner; Wolfgang Jost
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

3.  AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.

Authors:  Seye Abogunrin; Sarah Brand; Kamal Desai; Jerome Dinet; Sylvie Gabriel; Timothy Harrower
Journal:  Clinicoecon Outcomes Res       Date:  2015-09-09

Review 4.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

5.  Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study.

Authors:  Subsai Kongsaengdao; Benchalak Maneeton; Narong Maneeton
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-10       Impact factor: 2.570

6.  Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.

Authors:  Madhusubramanian Muthukumar; Kamal Desai; Seye Abogunrin; Timothy Harrower; Sylvie Gabriel; Jerome Dinet
Journal:  Clinicoecon Outcomes Res       Date:  2017-04-15

7.  Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study.

Authors:  Subsai Kongsaengdao; Narong Maneeton; Benchalak Maneeton
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-26       Impact factor: 2.570

8.  Usefulness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of cervical dystonia.

Authors:  Han Byul Lee; Young-Sil An; Hyun Young Lee; Jee Hyun Hwang; Hyun Jung Lee; Kil Yong Jeong; Jong Woo Kim; Shin-Young Yim
Journal:  Ann Rehabil Med       Date:  2012-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.